Gyre Therapeutics
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Gyre Therapeutics generated cash of $25,892,000, which is more than the previous year. Cash used in financing activities reached the amount of $2,500,000 last year. Net change in cash is therefore $8,334,000.
Cash Flow
| 2014 | -34.48M | 33.85M | 5.00M |
|---|---|---|---|
| 2015 | -19.11M | 37.35M | 9.31M |
| 2016 | -18.47M | -1.30M | 948K |
| 2017 | -19.94M | -11.25M | 35.4M |
| 2018 | -28.55M | -71.32M | 111.33M |
| 2019 | -43.61M | 27.39M | 327K |
| 2020 | -55.04M | 9.66M | 60.37M |
| 2021 | -83.75M | 48.18M | 49.55M |
| 2022 | -33.09M | 55.42M | -45.01M |
| 2023 | 25.89M | -19.76M | 2.5M |
GYRE Cash Flow Statement (2014 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 25.17M | 44.34M | 30.36M | 15.36M | 31.26M | 19.80M | 10.26M | 29.09M | 1.54M | 54.48M |
Operating activities | ||||||||||
Net income | -85.48M | -8.24M | -87.93M | -56.24M | -55.17M | -30.05M | -21.56M | -16.94M | -14.76M | -32.62M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||||||
Depreciation and amortization | 1.11M | 230K | 290K | 138K | 146K | 149K | 173K | 389K | 470K | 351K |
Stock-based compensation expense | 7.28M | 13.36M | 0 | 3.62M | 3.20M | 0 | 863K | 635K | 326K | 3.47M |
| Deferred income tax benefit | 7.28M | 13.36M | 0 | 3.62M | 3.20M | 0 | 863K | 635K | 326K | 3.47M |
| Changes in operating assets and liabilities: | ||||||||||
Accounts receivable, net | 1.30M | 1.61M | 1.49M | 11.68M | -15M | 0 | 7K | 461K | -79K | 1K |
Inventories | 1.74M | -879K | 3.88M | -3.04M | -490K | 0 | -479K | 956K | -1.35M | 0 |
Accounts payable | 192K | -6.22M | 500K | 1.65M | 3.03M | 500K | -90K | -102K | -4.27M | 0 |
Cash generated by operating activities | 25.89M | -33.09M | -83.75M | -55.04M | -43.61M | -28.55M | -19.94M | -18.47M | -19.11M | -34.48M |
Investing activities | ||||||||||
Purchases Of Investments | -15.73M | -50.51M | 0 | -97.63M | -129.97M | -198.91M | -25.47M | -13.40M | 0 | -7.16M |
Investments In Property Plant And Equipment | -8.51M | -4.99M | -839K | -267K | -64K | -376K | -23K | -468K | -272K | -4K |
Acquisitions Net | 4.02M | 55.49M | 0 | -9.93M | -27.45M | 0 | 0 | 890K | 23.93M | 0 |
Cash generated by investing activities | -19.76M | 55.42M | 48.18M | 9.66M | 27.39M | -71.32M | -11.25M | -1.30M | 37.35M | 33.85M |
Financing activities | ||||||||||
Common Stock Issued | 2.5M | 20K | 49.25M | 59.94M | 327K | 106.76M | 15.02M | 958K | 7.27M | 0 |
Payments for dividends | 0 | -45.03M | 0 | 0 | 0 | 0 | -3.95M | 0 | 0 | 0 |
Repurchases of common stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -82K | 0 |
Repayments of term debt | 0 | 0 | -6.70M | 0 | 0 | -5.08M | -14.31M | -14.34M | 235K | 0 |
Cash used in financing activities | 2.5M | -45.01M | 49.55M | 60.37M | 327K | 111.33M | 35.4M | 948K | 9.31M | 5.00M |
Net Change In Cash | 8.33M | -22.68M | 13.98M | 14.99M | -15.89M | 11.45M | 4.20M | -18.83M | 27.55M | 1.94M |
Cash at end of period | 33.50M | 21.66M | 44.34M | 30.36M | 15.36M | 31.26M | 14.47M | 10.26M | 29.09M | 56.43M |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source |